Peter Alan Lacey Sells 96,464 Shares of Hemostemix Inc. (CVE:HEM) Stock

Hemostemix Inc. (CVE:HEM) Director Peter Alan Lacey sold 96,464 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of C$0.18, for a total value of C$16,881.20.

Hemostemix Trading Up 12.5 %

Shares of CVE HEM opened at C$0.18 on Monday. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The business’s 50 day moving average price is C$0.21 and its 200-day moving average price is C$0.12. Hemostemix Inc. has a fifty-two week low of C$0.04 and a fifty-two week high of C$0.43. The company has a market cap of C$26.23 million, a price-to-earnings ratio of -5.25 and a beta of 0.20.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.